Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
54
ARKG Quote, Financials, Valuation and Earnings
Last price:
$23.68
Seasonality move
:
-1.84%
Day range:
$22.72 - $24.04
52-week range:
$22.27 - $34.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
6.9M
Avg. volume:
3M
1-year change:
-23.86%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
$23.68 | -- | -- | -- | $0.00 | 0% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$165.53 | -- | -- | -- | $1.17 | 0.71% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$9.89 | -- | -- | -- | $0.00 | 0% | -- |
|
IBB
iShares Biotechnology ETF
|
$132.73 | -- | -- | -- | $0.06 | 0.29% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$67.22 | -- | -- | -- | $0.01 | 0.05% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$91.28 | -- | -- | -- | $0.02 | 0.16% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | 3.421 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 1.249 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.318 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 1.446 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.301 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 2.133 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
ARK Genomic Revolution ETF vs. Competitors
-
Which has Higher Returns ARKG or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About ARKG or FBT?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe ARK Genomic Revolution ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is ARKG or FBT More Risky?
ARK Genomic Revolution ETF has a beta of 1.535, which suggesting that the stock is 53.464% more volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.671, suggesting its less volatile than the S&P 500 by 32.903%.
-
Which is a Better Dividend Stock ARKG or FBT?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.71% to investors and pays a quarterly dividend of $1.17 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or FBT?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns ARKG or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About ARKG or GNOM?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is ARKG or GNOM More Risky?
ARK Genomic Revolution ETF has a beta of 1.535, which suggesting that the stock is 53.464% more volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.532%.
-
Which is a Better Dividend Stock ARKG or GNOM?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or GNOM?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns ARKG or IBB?
iShares Biotechnology ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About ARKG or IBB?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than iShares Biotechnology ETF, analysts believe ARK Genomic Revolution ETF is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is ARKG or IBB More Risky?
ARK Genomic Revolution ETF has a beta of 1.535, which suggesting that the stock is 53.464% more volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.046%.
-
Which is a Better Dividend Stock ARKG or IBB?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iShares Biotechnology ETF offers a yield of 0.29% to investors and pays a quarterly dividend of $0.06 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or IBB?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
-
Which has Higher Returns ARKG or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About ARKG or PBE?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is ARKG or PBE More Risky?
ARK Genomic Revolution ETF has a beta of 1.535, which suggesting that the stock is 53.464% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.07%.
-
Which is a Better Dividend Stock ARKG or PBE?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or PBE?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns ARKG or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About ARKG or XBI?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe ARK Genomic Revolution ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is ARKG or XBI More Risky?
ARK Genomic Revolution ETF has a beta of 1.535, which suggesting that the stock is 53.464% more volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.394%.
-
Which is a Better Dividend Stock ARKG or XBI?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Biotech ETF offers a yield of 0.16% to investors and pays a quarterly dividend of $0.02 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or XBI?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
